PT98840A - Processo para a preparacao de composicoes farmaceuticas contendo anticorpos monoclonais homoconjugados - Google Patents

Processo para a preparacao de composicoes farmaceuticas contendo anticorpos monoclonais homoconjugados Download PDF

Info

Publication number
PT98840A
PT98840A PT98840A PT9884091A PT98840A PT 98840 A PT98840 A PT 98840A PT 98840 A PT98840 A PT 98840A PT 9884091 A PT9884091 A PT 9884091A PT 98840 A PT98840 A PT 98840A
Authority
PT
Portugal
Prior art keywords
antibodies
antibody
monoclonal antibodies
antigen
homoconjugate
Prior art date
Application number
PT98840A
Other languages
English (en)
Portuguese (pt)
Inventor
Howard V Raff
Edith Ann Wolff
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PT98840A publication Critical patent/PT98840A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT98840A 1990-08-31 1991-08-30 Processo para a preparacao de composicoes farmaceuticas contendo anticorpos monoclonais homoconjugados PT98840A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57572590A 1990-08-31 1990-08-31
US74866291A 1991-08-26 1991-08-26

Publications (1)

Publication Number Publication Date
PT98840A true PT98840A (pt) 1992-07-31

Family

ID=27076774

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98840A PT98840A (pt) 1990-08-31 1991-08-30 Processo para a preparacao de composicoes farmaceuticas contendo anticorpos monoclonais homoconjugados

Country Status (11)

Country Link
EP (1) EP0547137A4 (ja)
JP (1) JPH06500780A (ja)
KR (1) KR930702029A (ja)
AU (1) AU8506991A (ja)
CA (1) CA2090317A1 (ja)
FI (1) FI930846A (ja)
IE (1) IE913071A1 (ja)
IL (1) IL99363A0 (ja)
NZ (1) NZ239617A (ja)
PT (1) PT98840A (ja)
WO (1) WO1992004053A1 (ja)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2281300A (en) * 1993-08-26 1995-03-01 Merck & Co Inc Anti-HIV antibody oligomer
AU8296098A (en) 1997-07-08 1999-02-08 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
EP2845865A1 (en) 2004-11-12 2015-03-11 Xencor Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
WO2007044616A2 (en) 2005-10-06 2007-04-19 Xencor, Inc. Optimized anti-cd30 antibodies
PT2383297E (pt) 2006-08-14 2013-04-15 Xencor Inc Anticorpos otimizados que visam cd
EP2064240A2 (en) 2006-09-18 2009-06-03 Xencor, Inc. Optimized antibodies that target hm1.24
WO2009086320A1 (en) 2007-12-26 2009-07-09 Xencor, Inc Fc variants with altered binding to fcrn
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
WO2010112193A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
WO2010112194A1 (en) 2009-04-02 2010-10-07 F. Hoffmann-La Roche Ag Antigen-binding polypeptides and multispecific antibodies comprising them
ES2537100T3 (es) 2009-04-07 2015-06-02 Roche Glycart Ag Anticuerpos biespecíficos trivalentes
CA2757531A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Bispecific anti-erbb-3/anti-c-met antibodies
MX2011010158A (es) 2009-04-07 2011-10-17 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-2/anti-c-met.
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
SG10201408401RA (en) 2009-09-16 2015-01-29 Genentech Inc Coiled coil and/or tether containing protein complexes and uses thereof
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
BR112013001847A2 (pt) 2010-08-24 2016-05-31 Hoffmann La Roche anticorpo biespecífico, método de preparação do anticorpo biespecífico, do anticorpo biespecífico trivalente, métodos e composição farmacêutica
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
EP2812357B1 (en) 2012-02-10 2020-11-04 F.Hoffmann-La Roche Ag Single-chain antibodies and other heteromultimers
SG11201406238UA (en) 2012-04-05 2014-10-30 Hoffmann La Roche Bispecific antibodies against human tweak and human il17 and uses thereof
BR112014028368A2 (pt) 2012-06-27 2017-11-14 Hoffmann La Roche método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica
EP2867253B1 (en) 2012-06-27 2016-09-14 F. Hoffmann-La Roche AG Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
BR112014029403A2 (pt) 2012-07-04 2018-10-09 F. Hoffmann-La Roche Ag conjugados, anticorpo e formulação farmacêutica
EP2870180A1 (en) 2012-07-04 2015-05-13 F. Hoffmann-La Roche AG Anti-biotin antibodies and methods of use
ES2600154T3 (es) 2012-07-04 2017-02-07 F. Hoffmann-La Roche Ag Anticuerpos antiteofilina y métodos de uso
CN104341504B (zh) 2013-08-06 2017-10-24 百奥泰生物科技(广州)有限公司 双特异性抗体
AU2014368696A1 (en) 2013-12-20 2016-06-02 F. Hoffmann-La Roche Ag Humanized anti-Tau(pS422) antibodies and methods of use
CN105899540B (zh) 2014-01-03 2020-02-07 豪夫迈·罗氏有限公司 双特异性抗-半抗原/抗-血脑屏障受体的抗体、其复合物及它们作为血脑屏障穿梭物的应用
RU2682754C2 (ru) 2014-01-03 2019-03-21 Ф. Хоффманн-Ля Рош Аг Конъюгаты полипептидного токсина и антитела, соединенных ковалентной связью
CN105873615B (zh) 2014-01-03 2020-12-25 豪夫迈·罗氏有限公司 共价连接的helicar-抗helicar抗体缀合物及其用途
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
JP6721590B2 (ja) 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
CN107810196B (zh) 2015-06-24 2021-11-05 豪夫迈·罗氏有限公司 人源化的抗-Tau(pS422)抗体和使用方法
AU2018362747A1 (en) * 2017-11-07 2020-05-28 Hubit Genomix,Inc. Method for primary prevention of allergic disorders during infancy through IgE-class-specific immunosuppression

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422653D0 (en) * 1984-09-07 1984-10-10 Technology Licence Co Ltd Monoclonal antibodies
PT95809A (pt) * 1989-11-07 1991-09-13 Bristol Myers Squibb Co Processo para a preparacao de imunoglobulinas oligomericas, nomeadamente anticorpos monoclonais oligomericos

Also Published As

Publication number Publication date
EP0547137A4 (en) 1993-12-08
EP0547137A1 (en) 1993-06-23
WO1992004053A1 (en) 1992-03-19
FI930846A0 (fi) 1993-02-25
AU8506991A (en) 1992-03-30
JPH06500780A (ja) 1994-01-27
IE913071A1 (en) 1992-03-11
CA2090317A1 (en) 1992-03-01
IL99363A0 (en) 1992-08-18
KR930702029A (ko) 1993-09-08
FI930846A (fi) 1993-04-05
NZ239617A (en) 1993-11-25

Similar Documents

Publication Publication Date Title
PT98840A (pt) Processo para a preparacao de composicoes farmaceuticas contendo anticorpos monoclonais homoconjugados
JP3780315B2 (ja) 炎症性疾患の処置のための抗ｉｌ−８モノクローナル抗体
Woodley et al. Induction of epidermolysis bullosa acquisita in mice by passive transfer of autoantibodies from patients
Cunningham et al. Polyspecificity of antistreptococcal murine monoclonal antibodies and their implications in autoimmunity.
EP0764030B1 (en) Composition containing autoantibodies for tumor therapy and prophylaxis
EP0743856B1 (en) Antigen-based heteropolymers for treating autoimmune diseases
US4792447A (en) Anti-immunoglobulin toxin conjugates useful in the treatment of B cell tumors
PT1178824E (pt) Vacina de célula total contendo antígeno staphylococcus aureus
US20080038259A1 (en) LFA-1 alpaha subunit antibodies and methods of use
Egan et al. Protection of mice from experimental infection with type III group B Streptococcus using monoclonal antibodies.
US5717071A (en) Cross-protective human monoclonal antibody compositions
JP2005502610A (ja) フィブリンのｄ二量体断片に特異的なｄｄ−３ｂ６／２２から誘導されるヒト化抗体
EP0576439B1 (en) Monoclonal antibody against lps core
JP2639422B2 (ja) シュードモナスアエルギノーザ鞭毛に対するモノクローナル抗体
JPS60190721A (ja) 抗腫瘍特異的単クロ−ン性抗体の製造法
JPH10509948A (ja) Ｔ細胞受容体ペプチドに対するヒト抗体およびそれらの調製方法
US5858728A (en) Monoclonal antibody against LPS core
Koyama et al. Effect of chemical cationization of antigen on glomerular localization of immune complexes in active models of serum sickness nephritis in rabbits.
Simons et al. Expression of b 4 and b 5 ϰ light chain allotypes by B and pre‐B cells in allotype‐suppressed and neutralized b4b5 rabbits
Harris et al. Functional properties of anti-group B streptococcal monoclonal antibodies
JP4044733B2 (ja) ベロ毒素ｉｉを認識するヒト型化抗体、および該抗体を産生する細胞株
Landon et al. Therapeutic antibodies
US20030103977A1 (en) Antibodies to polysaccharide of C. neoformans
EP0368466B1 (en) Compositions and methods for the treatment and prevention of gram-negative bacterial infections
EP0450573A2 (en) Antibodies for the treatment and diagnosis of Pseudomonas aeruginosa infections

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19920318

FC3A Refusal

Effective date: 19981030